Gimeracil/oteracil/tegafur

Drug Profile

Gimeracil/oteracil/tegafur

Alternative Names: BMS-247616; S-1; Tegafur/gimeracil/oteracil potassium; Teysuno; TS-1; TS-ONE

Latest Information Update: 09 Dec 2016

Price : $50

At a glance

  • Originator Taiho Pharmaceutical
  • Developer Nordic Group; Shandong New age Pharmaceutical; Taiho Pharmaceutical; TTY Biopharm
  • Class Antineoplastics; Pyridines; Pyrimidinones; Small molecules; Triazines
  • Mechanism of Action Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Biliary cancer; Breast cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Pancreatic cancer
  • Phase III Cervical cancer; Hepatocellular carcinoma; Uterine cancer
  • Phase II Oesophageal cancer; Renal cancer
  • No development reported Prostate cancer

Most Recent Events

  • 31 Oct 2016 Shandong New age Pharmaceutical completes a phase II trial in Oesophageal cancer (First-line therapy) in China (unspecified route) (ChiCTR-TRC11001492)
  • 20 Oct 2016 Registered for Head and neck cancer in South Korea (PO) (TOT Biopharm website, October 2016)
  • 07 Oct 2016 Safety and efficacy data from a phase III trial in Non-small cell lung cancer presented at the European Society for Medical Oncology Congress (ESMO-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top